

University of Groningen

Novel perspectives for influenza vaccine formulation and administration

Saluja, Vinay

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2010

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Saluja, V. (2010). *Novel perspectives for influenza vaccine formulation and administration: L. lactis cell wall derived adjuvant, stable dry powder vaccines and mucosal vaccine delivery*. s.n.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

LIST OF PUBLICATIONS

From this thesis

V. Saluja, J-P. Amorij, M.L. van Roosmalen, *et al.* Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant. *AAPS Journal* 2010; 12 (2): 109-16.

V. Saluja, J-P. Amorij, J.C. Kapteyn, *et al.* A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation. *Journal of Controlled Release* 2010; 144(2): 127-33.

V. Saluja, W.L.J. Hinrichs and H.W. Frijlink. Dried influenza vaccines: Over the counter vaccines. *Human Vaccines* 2010; 6(10): 1-3.

V. Saluja, M.R. Visser, M.L. van Roosmalen, *et al.* Gastro-intestinal delivery of influenza subunit vaccine formulation adjuvanted with gram-positive enhancer matrix (GEM) particles. *European Journal of Pharmaceutics and Biopharmaceutics* (In press)

V. Saluja, M.R. Visser, W.T. Veer *et al.* Influenza antigen-sparing by immune stimulation with gram-positive enhancer matrix (GEM) particles. *Vaccine* (Accepted)

F. Geeraedts*, **V. Saluja***, W.T. Veer, *et al.* Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures. *AAPS Journal* 2010; 12 (2): 215-22. * **Both authors contributed equally.**

J-P. Amorij, **V. Saluja**, A.H. Petersen, *et al.* Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray freeze drying induces systemic, mucosal, humoral as well as cell-mediated immune responses in Balb/c mice. *Vaccine* 2007; 25(52): 8707-17.

Other Publications

V. Saluja, C. Avanti, E.L.P. van Streun, *et al.* Stabilization of proteins in liquid formulation using extremolytes. (*In Preparation*)

J. Prakash, **V. Saluja**, K. Poelstra, *et al.* Bioanalysis and Pharmacokinetics of the p38 MAPkinase inhibitor SB202190 in rats. *Journal of Chromatography B* 2005; 826(1-2): 220-5.

T. Velpandian, **V. Saluja**, A.K. Ravi, *et al.* Evaluation of the stability of extemporaneously prepared topical formulation of Mitomycin C. *Journal of Ocular Pharmacology and Therapeutics* 2005; 21(3): 217-22.

J. Prakash, M. Sandovici, **V. Saluja**, *et al.* Intracellular Delivery of the p38 Mitogen-Activated Protein Kinase Inhibitor SB202190 [4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in Renal Tubular Cells: A Novel Strategy to Treat Renal Fibrosis. *Journal of Pharmacology and Experimental Therapeutics* 2006; 319(1): 8-19.

Conference Abstracts

V. Saluja, *et al.* Influenza antigen-sparing (25x) by adjuvantation of subunit vaccine with gram-positive enhancer matrix (GEM) particles. **Options for the Control of Influenza VII**, 3-7 Sept. 2010, Hong Kong SAR, China. (**Poster presentation**)

V. Saluja, *et al.* Development of stable and dry pulmonary formulation of influenza subunit vaccine. **Pharmacy integrating lectures** (PIL meeting) 10th May, 2010, University of Groningen, Groningen, The Netherlands. (**Oral Presentation**)

V. Saluja, *et al.* Thermo-stabilizing proteins: What can we learn from extremophiles? **TI Pharma Spring Meeting**, 15th April 2010, Utrecht, The Netherlands. (**Oral presentation**)

V. Saluja, *et al.* Stabilization of influenza whole inactivated H5N1 vaccine by lyophilization. **AAPS Annual Meeting and Exposition**, 8-12 November 2009, Los Angeles, USA. (**Poster presentation**)

V. Saluja, *et al.* Buffers can influence the stabilization of influenza subunit vaccine during the spray drying and spray freeze drying.

- **PharmSciFair**, 8-12 June 2009, Nice, France. (**Oral presentation**)

- **TI Pharma Spring Meeting**, 23rd April 2009, Utrecht, The Netherlands.
(**Oral presentation**)

V. Saluja, *et al.* Gram positive enhancer matrix (GEM) particles: A novel adjuvant for systemic and mucosal influenza immunization. **Vaccine Congress**, 9-11 December 2007, Amsterdam, The Netherlands. (**Poster presentation**)